HGH Sermorelin Definition Sermorelin is a form of growth hormone releasing factor (GRF) that contains only the first 29 of the 44 amino acids produced by neurosecretory neurons in the brain. In the 1970's, Nobel Laureates, R.Guilleman and A. Shalley found that only the first 29 amino acids are responsible for stimulating pituitary production and secretion of HGH. As a result of their research the chemical name for Sermorelin is GRH 1-29 NH 2. Sermorelin is NOT the same as human growth hormone (HGH). It is a growth hormone secretagogue, which means that it stimulates the pituitary gland to produce and secrete growth hormone. Sermorelin is a small peptide containing only 29 amino acids whereas HGH is a much larger molecule containing 191 amino acids. Ordering your Sermorelin kit from The HGH Network. When you order your Semorelin kit through The HGH Network, you'll receive all test kits necessary to determine the level of sermorelin your body requires as well as sermorelin and all necessary ingredients for a month's program, plus you'll speak with our staff medical doctor and our . Click on the Buy Now button to get started!

 

The Many Benefits Of HGH Sermorelin Program

It was discovered that there were many more benefits experienced from being on this program.

Here are a Few:

a) Increases the development of lean body mass through the development of new muscle cells

b) Reduces body fat through lipolysis

c) Increases vitality and energy

d) Accelerates healing from injuries

e) Enhances the bodies immune system

f) Improves sleep quality

g) Increases calcium retention, and strengthens and increases the mineralization of bone or bone density.

h) Increases sexual libido

i) Fewer wrinkles

j) Memory improvement

Sermorelin Research Report

SERMORELIN
(Growth Hormone Releasing Hormone)

**Information obtained from Clinical Pharmacology, published medical journal articles and medical conference presentations.

Product Description and Dose Selection
Sermorelin (ser-moe-REL-in) is a biological active analog of growth hormone releasing hormone (GHRH) that is produced by the human brain to stimulate production and release of growth hormone by the pituitary gland. During youth, ample amounts of GHRH are produced so that the pituitary is able to provide the body with sufficient growth hormone to sustain health, vitality and otherwise normal aspects of form and function. However, during aging GHRH declines, causing reduced production and secretion from the pituitary hGH and thereby increasing the sequelae of growth hormone insufficiency that erodes health, vigor and vitality during later life. Unlike hGH, Sermorelin affects a more primary source of age-failure in the GH neuroendocrine axis, has more physiological activity, a better safety profile, and it’s use in anti-aging medicine is not prohibited. Thus, Sermorelin should be considered a valuable alternative to hGH by anti-aging practitioners seeking to provide the best and most contemporary interventions in aging for their patients.

Description: Sermorelin is a parenteral drug used as a growth hormone releasing hormone (GHRH). This synthetic, 29-amino acid polypeptide is the amino-terminal segment of the naturally occurring human growth hormone releasing hormone (GHRH) and consists of 44 amino acid residues. Sermorelin appears to be equivalent to endogenous GHRH in its ability to stimulate growth hormone secretion in humans. Sermorelin is used to treat growth hormone deficiency (e.g., Geref®, FDA-approved in October 1997) and also as a diagnostic agent to evaluate the ability of the somatotroph of the pituitary gland to secrete growth hormone (e.g., Geref® Diagnostic, FDA-approved in 1991). Serono Inc. announced in March 2002 that the manufacture of Geref® would be discontinued by November 2002. Currently Sermorelin is compounded into multi-dose vials containing sufficient product for 30 days of therapy. Each vial contains from 6 to 12mg of Sermorelin as a sterile, lypholized powder. Sufficient diluent (3ml’s sterile water for injection) is provided so that each 0.1ml of the reconstituted solution contains daily doses ranging from 200 to 400mcg Sermorelin. Recommended doses include the following:
• 6mg MDV: 200mcg/0.1ml/day for men with BMI between 18.5-24.9
• 9mg MDV: 300mcg/0.1ml/day for men or women with BMI between 25-29.9
• 12mg MDV: 400mcg: 400mcg/0.1ml/day for men or women with BMI between 25-29.9

These recommended dosages are based upon the results of clinical testing in men of normal weight in whom 200mcg/day increased pituitary reserve of hGH (as indicated by enhanced responses to provocative testing) and increased ICG-1. A sample set of the data are provided in the following table. IGF-1 increased in men ranging in age from 50- 66 years after 30 consecutive days of subcutaneous administration of 200mcg Sermorelin. Since estrogen and adiposity negatively effect growth hormone action on the liver to produce IGF-1, higher doses of Sermorelin are recommended for women and men with high BMIs.

Mechanism of Action: Sermorelin increases plasma growth hormone (GH) concentrations by direct stimulation of the pituitary gland. •Diagnostic use: In diagnostic use, a normal plasma GH response to sermorelin demonstrates that the somatotroph of the pituitary is intact but does not release GH on its own, and these patients may respond to GHRH therapy. A normal response to sermorelin does not always exclude GH deficiency however, because deficiency can be the result of hypothalamic dysfunction in the presence of an intact somatotroph. Clinical trials have indicated that GH deficiency is frequently not due to somatotroph failure. If no GH is secreted in response to the sermorelin test, a need for GH replacement is usually indicated.
•Therapeutic use: Most people with idiopathic GH deficiency have an intact pituitary but it does not release adequate amounts of GH. GHRH therapy may treat these patients. Sermorelin (synthetic GHRH) works to stimulate the pituitary to restore physiologic pulses of GH, helping the body to use its natural reserves. Secreted endogenous GH acts on peripheral tissues, and these tissues respond to GH and produce insulin-like growth factor 1 (IGF-1).
Contraindications/Precautions:
Contraindications: Hypersensitivity to sermorelin or any of the components of the injection.
Precautions include:
Elderly: Clinical studies of sermorelin diagnostic did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range. Hypothyroidism: Untreated hypothyroidism can jeopardize the response to sermorelin. Thyroid hormone determinations should be performed before the initiation and during therapy. Thyroid hormone replacement therapy should be initiated when indicated. Intracranial lesions: Patients with GH deficiency secondary to an intracranial lesion were **Above information obtained from Clinical Pharmacology, published medical journal articles and medical conference presentations. not studied in clinical trials; sermorelin treatment is not recommended in such patients. Obesity, hyperglycemia or hyperlipidemia: Subnormal GH responses have been seen in obesity and hyperglycemia, and in patients with elevated plasma fatty acids. Pregnancy and Lactation: FDA pregnancy risk category C. Exercise caution during lactation; it is not known if this drug is excreted in breast milk. Laboratory Tests: Serum levels of inorganic phosphorus, alkaline phosphatase, GH and IGF-I may increase with therapeutic use.
Drug Interactions: NOTE: Drug interactions with diagnostic use may be different from drug interactions with therapeutic use of this drug.
Drug Interactions with Therapeutic Use:
•Corticosteroids: Glucocorticoids may inhibit the response to sermorelin.
Drug Interactions with Diagnostic Use:
•Exogenous Growth Hormone (GH) therapy: Discontinue at least 1 week before using sermorelin as a diagnostic agent.
•Insulin, glucocorticoids, cyclooxygenase inhibitors (aspirin, indomethacin, NSAIDs), octreotide or somatostatin: These agents directly affect the pituitary secretion of somatotropin.
•Clonidine, levodopa, and insulin-induced hypoglycemia: Somatotropin concentrations can be transiently elevated.
•Antimuscarinic Agents: May blunt response to sermorelin test.
•Antithyroid Agents: Hypothyroidism can jeopardize the response to sermorelin test.
Adverse Reactions: The most common side effects with SC injection include local injection reactions (occurring in about 16%; pain, swelling or redness), but discontinuation of therapy is rare. Other treatment-related adverse reactions with occurrence rates of less than 1% include headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria. The following side effects may occur with IV diagnostic use: transient warmth or flushing of the face; injection site reactions (pain, redness or swelling); nausea/vomiting; headache; dysgeusia; pallor; chest tightness (unspecified). Heart rate/blood pressure changes may occur with inadvertent overdosage. Antibody formation to sermorelin has been reported frequently after chronic SC administration of large doses. The clinical significance is unknown, but antibodies do not appear to affect growth or appear to be related to a specific ADR profile. No generalized allergic reactions have been reported. A temporary allergic reaction described as severe redness, swelling and urticaria at the injection sites has been reported in one patient who developed antibodies. Single doses (like in diagnostic use) are unlikely to result in hypersensitivity reactions. Patients should seek medical attention for suspected allergic reactions.
Available As:
• 6mg MDV: 200mcg/0.1ml/day for men with BMI between 18.5-24.9
• 9mg MDV: 300mcg/0.1ml/day for men or women with BMI between 25-29.9
• 12mg MDV: 400mcg/0.1ml/day for men or women with BMI between 25-29.9

 

HGH Shot Fear Factor

Important Information on the actual HGH shots

The actual shot used for the HGH is a small ¼ inch needle similar to what is used for diabetics for their daily insulin shots. The ¼ inch needle shot is self administered near the belly button directly into the “fat fold” in the stomach area. There is, per survey, very little sensation on injection and can be easily done by anyone who wants to help. The glass vial that the actual HGH is in for consumption is simple to use and is kept in the refrigerator. It is suggested that one has a partner do the first few injections, until you can see for yourself how effortless it is and how you pretty much don’t feel anything when the injection goes in; you’ll soon be doing it yourself.

The quarter inch, self injecting stomach fold protocal is special to only one HGH clinic/pharmacy provider currently on the market. We use the natural version of the HGH.

The HGH shots referred to by Dr. Simeons in his "pounds and Inches" manuscript can still be done at your own home. We handle everything. Hit the buy now button and you will be sent a health questionnaire to fill out. You will be contacted by a Certified Doctor that will approve your participation in the HGH Protocol. Remember, the average person loses a full pound a day, and in the fat store areas of the body. And best of all, you will not gain the weight back!